JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 3, 2003; DOI: 10.1124/jpet.103.054155


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.054155v1
307/1/110    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koyano, S.
Right arrow Articles by Sawada, J.-i.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koyano, S.
Right arrow Articles by Sawada, J.-i.


Received for publication May 8, 2003.
Revised June 11, 2003.
Accepted for publication June 23, 2003.

Functional analysis of three genetic polymorphisms in the glucocorticoid receptor gene

Satoru Koyano 1*, Yoshiro Saito 1, Michiyo Nagano 1, Keiko Maekawa 1, Yutaka Kikuchi 1, Norie Murayama 1, Tomofumi Fujino 1, Shogo Ozawa 1, Toshiharu Nakajima 2, Kenji Matsumoto 2, Hirohisa Saito 2, Jun-ichi Sawada 1

1 National Institute of Health Sciences 2 National Center for Child Health and Development

* Address correspondence to: E-mail: skoyano{at}nihs.go.jp

Abstract

Glucocorticoids are widely used as potent anti- inflammatory drugs. Glucocorticoids exert their pharmacological effects by binding to a glucocorticoid receptor (GR), which promotes expression of its target genes, or suppresses transcription mediated by other transcriptional factors, such as NF-{kappa}B. In order to identify genetic polymorphisms affecting glucocorticoid responses, the GR gene were sequenced and two novel single nucleotide alterations, 1510A>T (T504S) and 1952C>T (S651F), were identified in addition to an adenine base insertion at nucleotide 2314 (2314insA). mRNA expression levels of T504S and S651F were comparable to that of the wild type (WT), whereas the mRNA level of 2314insA was reduced to ~36% of the WT level. Protein expression was reduced to ~66% of WT levels in S651F and to ~6% in 2314insA. No significant change was seen in the T504S variant levels. The instability of the 2314insA mRNA, S651F protein, and 2314insA protein was confirmed by time-course experiments. The transcriptional activity of S651F and 2314insA was also reduced to approximately 63% and 2% of the WT levels, respectively, in the luciferase reporter assay. Moreover, the inhibitory effect of GR on NF-{kappa}B transactivation was reduced to approximately 81% and 12% of the WT levels for S651F and 2314insA, respectively. These results indicated that the overall transcriptional activity and inhibitory effect on NF-{kappa}B transactivation of S651F and 2314insA have partially reduced and almost abrogated, respectively, almost paralleling their reduced protein expression levels caused by mRNA and/or protein instabilities. Thus, these two variations were suggested to influence the response to glucocorticoid treatment.


Key words: functional change, glucocorticoid receptor, nuclear factor-kappaB, single nucleotide polymorphism, stability, transcription


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. Koyano, Y. Saito, H. Fukushima-Uesaka, S. Ishida, S. Ozawa, N. Kamatani, H. Minami, A. Ohtsu, T. Hamaguchi, K. Shirao, et al.
FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION
Drug Metab. Dispos., August 1, 2005; 33(8): 1254 - 1260.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Koyano, K. Kurose, Y. Saito, S. Ozawa, R. Hasegawa, K. Komamura, K. Ueno, S. Kamakura, M. Kitakaze, T. Nakajima, et al.
FUNCTIONAL CHARACTERIZATION OF FOUR NATURALLY OCCURRING VARIANTS OF HUMAN PREGNANE X RECEPTOR (PXR): ONE VARIANT CAUSES DRAMATIC LOSS OF BOTH DNA BINDING ACTIVITY AND THE TRANSACTIVATION OF THE CYP3A4 PROMOTER/ENHANCER REGION
Drug Metab. Dispos., January 1, 2004; 32(1): 149 - 154.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.